Respiratory syncytial virus vaccine

Uncommon card · No. 169812

A respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine that protects against respiratory syncytial virus. RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year. The RSV vaccines Arexvy (GSK), Abrysvo (Pfizer), and Mresvia (Moderna) are approved for medical use in the United States. Arexvy is approved for medical use in the United States, in the European Union, and in Canada for people aged 60 years of age and older. Arexvy is approved in the US for people aged 50–59 years of age who are at increased risk. In the United States, the Centers for Disease Control and Prevention (CDC) recommends a single dose of an RSV vaccine for all adults aged 75 years and older and for adults aged 50–74 years who are at increased risk of severe RSV illness. RSV vaccination is not currently recommended annually; people who have already received an RSV vaccine are not recommended to receive another dose at this time. A 2013 study led to the 2023 approval of RSV...

Read on Wikipedia